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Pharmacological cardioprotection with opioids in humans has been targeted as a potential method that may demonstrate efficacy for treatment of acute myocardial infarction (Bell et al., 2000) . Morphine is commonly administered during an acute myocardial infarction as a method of pain relief at a loading dose ranging from 0.06-0.11mg/kg (4-8mg/70kg), with additional morphine doses of 0.03-0.14mg/kg administered every 5-15 minutes. Although more uncommon, the total morphine dose in some patients experiencing a myocardial infarction can reach 2-5mg/kg (Antman et al., 2000) . Moreover, morphine is routinely administered during an acute myocardial infarction in combination with nonsteroidal anti-inflammatory agents (NSAIDs) to achieve an anti-thrombotic effect with aspirin doses ranging from 2.3-4.6mg/kg (160-325mg/70kg) (Hollander, 2000) .
Previously, morphine has been shown to mimic ischemic preconditioning (IPC) when administered to rats prior to ischemia (Schultz et al., 1997) and also reduced infarct size when given prior to reperfusion (Gross et al., 2004) . However, it is unknown in animal models whether morphine administered following reperfusion can reduce infarct size. Additionally, although patients commonly receive a combination of NSAIDs and morphine in the emergency room during a myocardial infarction, no studies have examined if aspirin or ibuprofen has an adverse or beneficial effect on morphine-induced infarct size reduction. Although there is strong clinical evidence that aspirin reduces mortality rate from a myocardial infarction following chronic oral administration (Hennekens et al., 1997) , it is controversial in animal models as to whether aspirin when given acutely reduces infarct size or is detrimental Rossoni et al., 2001; Lepran et al., 1981; Bonow et al., 1981) . Additionally, a number of animal models have also shown that ibuprofen can reduce infarct size (Jugdutt et al., 1980; Kirlin et al., 1982; Romson et al., 1982) . However, it has not been established whether aspirin or ibuprofen JPET #64667 Page 5 reduce infarct size when administered as a single dose just prior to or following reperfusion.
Moreover, aspirin or ibuprofen may interact with morphine since 12-lipoxygenase(12-LO) is an end effector of δ opioid-induced delayed cardioprotection (Patel et al., 2003) .
Therefore, the objective of this study was to determine whether morphine, aspirin or ibuprofen reduces infarct size when administered either 5 minutes prior to reperfusion or 10 seconds after reperfusion and what effect the concomitant administration of aspirin or ibuprofen with morphine has on infarct size reduction. Furthermore, we examined if sub-threshold cardioprotective doses of aspirin or ibuprofen in combination with a sub-threshold dose of morphine can reduce infarct size. Lastly, we determined if the mechanism of acute infarct size reduction produced by these agents is mediated by 12-LO.
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Methods
The experimental procedures and protocols used in this study were reviewed and approved by the Animal Care and Use Committee of the Medical College of Wisconsin and conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Pharmacological Agents
The agents used for this study included morphine sulphate (Research Biochemicals International, RBI, Natick, Massachusetts), aspirin (acetylsalicylic acid, Sigma, Saint Louis, Missouri) and ibuprofen (Sigma, Saint Louis, Missouri). Additional agents included the 12-LO inhibiter, baicalein (Biomol, Plymouth Meeting, Pennsylvania) and the 12-LO metabolite 12-(S)-Hydroxyeicosa-5Z,8Z,10Z,14Z-tetraenoic acid (12(S)-HETE, Biomol, Plymouth Meeting, Pennsylvania). Morphine sulphate was dissolved in water. Aspirin, ibuprofen and 12(S)-HETE were dissolved in 95% ethanol, while baicalein was dissolved in dimethyl sufloxide (DMSO, Sigma, Saint Louis, Missouri) and diluted 1:2 in water(Sigma, Saint Louis, Missouri).
Experimental Protocols: Infarct Size Studies
Male Sprague-Dawley rats (215-300g) were obtained from Harlan (Indianapolis, Indiana) and were used for an in vivo model of ischemia and reperfusion. The general surgical protocol and determination of infarct size have been described previously in detail .
All agents were administered IV, except 12(S)-HETE, which was delivered through the left atrial appendage via a 30 gauge needle. 12(S)-HETE was administered via the left atrial appendage JPET #64667 Page 7 since previously it has been shown that 12(S)-HETE can be metabolized by the lung (PaceAsciak et al., 1983) . Hemodynamics, including heart rate, mean arterial pressure and rate pressure product were quantified during baseline, 15 minutes into ischemia and at 2 hours of reperfusion and compared to vehicle treated rats for each group.
Following surgical intervention and stabilization, rats were separated into groups (n=6-8 per group) to undergo the experimental protocols outlined (Figure 1 ). For the first part of the study, rats were subjected to treatment with morphine, aspirin, ibuprofen or ethanol vehicle 5 minutes prior to reperfusion. Morphine (0.1mg/kg, 0.2mg/kg and 0.3mg/kg), aspirin (0.6mg/kg, 1mg/kg and 3mg/kg) or ibuprofen (0.6mg/kg, 1mg/kg and 3mg/kg) were administered at 3 different doses. Secondly, morphine (0.3mg/kg), aspirin (3mg/kg), ibuprofen (3mg/kg) or ethanol vehicle were administered 10 seconds after reperfusion.
To examine the interactions of aspirin and ibuprofen with morphine, aspirin (1mg/kg or 3mg/kg) or ibuprofen (3mg/kg) was administered 2 minutes prior to morphine (0.3mg/kg) given 5 minutes prior to reperfusion. Aspirin or ibuprofen was also administered with morphine (0.2mg/kg) to determine if sub-threshold doses of these agents that do not individually reduce infarct size are effective when given in combination.
To discern the effects of 12-LO on morphine or ibuprofen-induced cardioprotection, the 12-LO inhibitor, baicalein (3mg/kg), was administered 10 minutes prior to ischemia alone or in combination with morphine (0.3mg/kg), ibuprofen (3mg/kg) or morphine (0.2mg/kg) plus ibuprofen (0.6mg/kg). A subset of rats also received DMSO vehicle, 10 minutes prior to ischemia. Additional rats received 12(S)-HETE (15µg/kg), 5 minutes prior to reperfusion.
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Statistical Measurements
All values were denoted as mean ± SEM. Statistical significance was determined by performing a one-way ANOVA with Bonferroni's correction for multiplicity. Values significantly different from vehicle were indicated ** (P value of <0.01).
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Results
One hundred and sixty-two rats were used to obtain 142 successful experiments. Twenty rats were excluded due to ventricular fibrillation during occlusion or reperfusion (17), the suture loosening during occlusion (1), diarrhea (1) and anesthetic overdose (1).
Hemodynamics:
Heart rate, mean arterial pressure and rate pressure product were quantified during baseline, 15 minutes into ischemia and at 2 hours of reperfusion and compared to vehicle treated rats for each group (Table 1) . No significant differences were found for heart rate, mean arterial pressure and rate pressure product at baseline, 15 minutes of occlusion or 2 hours of reperfusion for each group when compared to vehicle treated rats for each protocol. 59.0 ± 1.4, 58.6 ± 4.7, 57.6 ± 2.8 versus 59.1 ± 1.7%, respectively). Interestingly, concomitant administration of aspirin (0.6mg/kg) with morphine (0.2mg/kg) did not result in a reduction in infarct size, while administration of ibuprofen (0.6mg/kg) with morphine (0.2mg/kg) reduced infarct size when compared to ethanol vehicle (Figure 5: 53.1 ± 4.8, 43.9 ± 1.6** versus 59.1 ± 1.7%, respectively).
12-LO As A Mediator of Morphine or Ibuprofen-Induced Cardioprotection:
Morphine (0.3mg/kg), ibuprofen (3mg/kg) and concomitant administration of morphine (0.2mg/kg) plus ibuprofen (0.6mg/kg) reduced infarct size when administered 5 minutes prior to JPET #64667 Page 11 reperfusion when compared to DMSO vehicle (Figure 6: 42.3 ± 1.5**, 40.8 ± 2.8**, 43.9 ± 1.6** versus 59.7 ± 1.5%, respectively). Administration 10 minutes before ischemia of baicalein abrogated the reduction in infarct size produced by morphine (0.3mg/kg), ibuprofen (3mg/kg) and morphine (0.2mg/kg) plus ibuprofen (0.6mg/kg) compared to DMSO vehicle (Figure 6 : 51.0 ± 4.6, 64.0 ± 2.1, 57.5 ± 1.8 versus 59.7 ± 1.5%, respectively). Baicalein alone administered 10 minutes prior to ischemia had no effect on infarct size when compared to DMSO vehicle ( Figure   6 : 61.3 ± 0.9 versus 59.7 ± 1.5%, respectively). Administration of 12(S)-HETE (15µg/kg), 5 minutes prior to reperfusion also reduced infarct size compared to DMSO vehicle (Figure 6: 45.2 ± 2.5** versus 59.7 ± 1.5%, respectively) and ethanol vehicle administered prior to reperfusion (45.2 ± 2.5** versus 59.1 ± 1.7%, respectively).
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Discussion
This is the first study to show that morphine and ibuprofen, but not aspirin, can individually or in combination reduce infarct size when administered at clinically relevant doses 5 minutes prior to reperfusion, whereas all agents administered 10 seconds after reperfusion failed to reduce infarct size. We also determined that aspirin, but not ibuprofen, abolished morphine-induced cardioprotection at clinically relevant doses. The combination of morphine and ibuprofen also reduced infarct size when given at sub-threshold doses that did not reduce infarct size when administered alone. Morphine and ibuprofen-induced infarct size reduction also occurred via 12-LO and could be mimicked by the 12-LO metabolite, 12(S)-HETE.
The protection afforded by morphine when given 5 minutes prior to reperfusion in this study and our previous study was found to produce similar infarct size reducing capabilities when compared to morphine administered 10 minutes prior to ischemia (Gross et al., 2004) .
Moreover, morphine administration is required prior to reperfusion to obtain a reduction in infarct size, indicating a role for morphine in preserving the myocardium from reperfusion injury.
Ibuprofen administered 5 minutes prior to reperfusion reduced myocardial infarct size at 3mg/kg, while administration 10 seconds after reperfusion produced no effect. Similar effects were seen in dogs where ibuprofen was infused at higher doses than those used in our study and continued for several hours during both the ischemia and reperfusion periods (Jugdutt et al., 1980; Kirlin et al., 1982; Romson et al., 1982) . Hence, our study refines the window of protection for ibuprofen as being beneficial when administered just prior to reperfusion.
Previous studies in cats show a beneficial effect of ibuprofen as indicated by a reduction of creatine phosphokinase release, a restoration of S-T segment elevation, and prevention of JPET #64667 Page 13 proteolysis (Lefer et al., 1979) . Furthermore, studies in isolated rat hearts have also shown that ibuprofen improves functional recovery (Karmazyn, 1986) . However, conflicting reports have shown that ibuprofen does not improve functional recovery of isolated feline and pig hearts Clement et al., 1990) . Although there is conflicting evidence suggesting that ibuprofen may not improve cardiac functional recovery, our data and those of others suggest that ibuprofen reduces infarct size in different animal models and that the cardioprotective benefits of ibuprofen likely extend to humans (Walinsky et al., 1983) .
Conflicting results have also been reported for the role of aspirin in cardioprotection.
While some reports have found a beneficial effect of aspirin to reduce infarct size Rossoni et al., 2001) , others have shown no effect (Lepran et al., 1981; Bonow et al., 1981 ). The differences between these studies are likely attributed to the duration of aspirin administration prior to a myocardial infarction, since chronic administration of aspirin prior to ischemia and reperfusion reduced infarct size Rossoni et al., 2001) , while acute administration up to 1 hour prior to ischemia demonstrated no reduction of infarct size (Lepran et al., 1981; Bonow et al., 1981) . These latter studies, in addition to our findings, would further suggest that the cardioprotection afforded by aspirin is attributed to its anti-thrombotic effects that occurs more than 1 hour after aspirin administration (Hirsh et al., 1992) , however, when aspirin is administered acutely during ischemia or reperfusion, there is no immediate beneficial effect on infarct size (Lepran et al., 1981; Bonow et al., 1981) . It is unknown whether prophylactic treatment of aspirin will abrogate acute morphine-induced infarct size reduction, however, it has been suggested that aspirin may diminish the beneficial effects of angiotensinconverting enzyme inhibitors in humans (Przyklenk and Heusch, 2003) .
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No other studies have examined the interactions of aspirin or ibuprofen with morphine and its ability to reduce infarct size. Surprisingly, our results suggest that aspirin abrogates morphine-induced cardioprotection, while ibuprofen does not effect morphine-induced cardioprotection. Furthermore, the simultaneous administration of these agents, at doses which do not reduce infarct size individually, are effective in combination. Since both morphine and ibuprofen at their highest doses induced similar reductions in infarct size compared to the concomitant administration of ibuprofen and morphine, it would also indicate that the mechanism of infarct size reduction is saturated and a similar pathway of cardioprotection exists for both morphine and ibuprofen.
The ability of morphine or ibuprofen to protect the myocardium when given prior to reperfusion, but not after reperfusion, may involve a reduction in free radical generation, an event found to be most prominent during the first 10 minutes of reperfusion (Zweier et al., 1989; Garlick et al., 1987) . The generation of oxygen derived free radicals (OFRs) has also been found to damage membrane lipids during reperfusion (Ambrosio et al., 1991) . Interestingly, the conversion of arachidonic acid to 12-HETE has been shown to be attenuated by generation of OFRs, while conversely, scavengers of OFRs have been found to cause an elevation of 12-HETE (Muller and Gawlik, 1997) . The recovery of left ventricular developed pressure by 12(S)-HETE was also blocked by the mitochondrial K ATP channel antagonist, 5-hydroxydecanoic acid (5HD) (Chen et al., 1999) . The mitochondrial K ATP channel has previously been identified as a source of oxygen radical generation (Pain et al., 2000) , and suggests perhaps an interaction occurs between the K ATP channel, OFRs and 12-HETE.
Several different types of 12-LO exist, including leukocyte, epidermal and platelet 12-LO. Interestingly, leukocyte 12-LO knockout mice abolished IPC-induced infarct size reduction JPET #64667 Page 15 and these mice also show an increased sensitivity to ADP-induced platelet aggregation (Gabel et al., 2001; Johnson et al., 1998) . 12-HETE administration to leukocyte 12-LO deficient mice also reversed ADP-induced platelet aggregation (Johnson et al., 1998) . The human homologue of rat leukocyte 12-LO is the 15-lipoxygenase enzyme (15-LO) that produces 15-HETE as a product (Watanabe et al., 1993) . Addition of ibuprofen to human peripheral blood polymorphonuclear leukocytes (PMNs) was found to selectively activate 15-LO and increase 15-HETE concentrations (Vanderhoek and Bailey, 1984) . Production of 15-HETE was elevated 9 fold for PMNs treated with ibuprofen, however, aspirin and indomethacin only produced a mild 1.5-2 fold elevation in 15-HETE.
The results of our study must be considered with potential limitations, including the extension of these findings from rats to humans. Many additional agents, such as thrombolytics, beta blockers and nitroglycerin, are also commonly given during or prior to reperfusion (Antman et al., 2000) . Hence, the ability for morphine or ibuprofen to reduce infarct size in the presence of additional agents commonly given during a myocardial infarction are unknown. The pharmacological agents used in this study may have additional nonspecific effects, however, the doses of ibuprofen and aspirin given were similar to those commonly administered in the clinic.
Ibuprofen and aspirin were also administered intravenously, rather than orally. Although 12-HETE was not measured in this study, we previously showed that the selective δ opioid agonist, SNC-121, elevated 12-HETE production during reperfusion in a model of delayed infarct size reduction (Patel et al., 2003) .
These data suggest that timely administration of morphine or ibuprofen prior to reperfusion may attenuate reperfusion injury and reduce infarct size during an acute myocardial infarction. This study also suggests that acute aspirin administration is detrimental to morphine-JPET #64667 Page 16 induced cardioprotection. Furthermore, ibuprofen, instead of aspirin, may be more beneficial to patients during an acute myocardial infarction because of its ability to reduce infarct size both individually and in combination with morphine. These data also implicate 12-HETE in morphine and ibuprofen-induced infarct size reduction.
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